Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Extends Gingivitis Draft Guidance Comment Period To Oct. 28

This article was originally published in The Tan Sheet

Executive Summary

FDA will accept comments on a 1draft guidance addressing antigingivitis drug development and evaluation until Oct. 28, 2005, the agency said in an Aug. 24 Federal Register notice

You may also be interested in...



FDA gingivitis guidance

OTC gingivitis products should carry the labeling claim "helps prevent gingivitis" while Rx drugs may include the more scientific phrase "reduction of disease incidence," FDA recommends in a FDL-1draft guidance published in the Federal Register June 28. "Gingivitis: Development & Evaluation of Drugs for Treatment or Prevention" focuses on trial design issues and clinical assessments involved with developing both Rx and OTC products for the condition. Recommended inclusion criteria for clinical trials such as "a specified number of teeth present" and "a qualifying baseline plaque index" are provided by the agency, while exclusion criteria include "chronic disease with concomitant oral manifestations." A definition of the difference between prevention and treatment of the condition also is included...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel